RT Journal Article
SR Electronic
T1 Multi-ancestry Polygenic Mechanisms of Type 2 Diabetes Elucidate Disease Processes and Clinical Heterogeneity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.28.23296294
DO 10.1101/2023.09.28.23296294
A1 Smith, Kirk
A1 Deutsch, Aaron J.
A1 McGrail, Carolyn
A1 Kim, Hyunkyung
A1 Hsu, Sarah
A1 Mandla, Ravi
A1 Schroeder, Philip H.
A1 Westerman, Kenneth E.
A1 Szczerbinski, Lukasz
A1 Majarian, Timothy D.
A1 Kaur, Varinderpal
A1 Williamson, Alice
A1 Claussnitzer, Melina
A1 Florez, Jose C.
A1 Manning, Alisa K.
A1 Mercader, Josep M.
A1 Gaulton, Kyle J.
A1 Udler, Miriam S.
YR 2023
UL http://medrxiv.org/content/early/2023/09/29/2023.09.28.23296294.abstract
AB We identified genetic subtypes of type 2 diabetes (T2D) by analyzing genetic data from diverse groups, including non-European populations. We implemented soft clustering with 650 T2D-associated genetic variants, capturing known and novel T2D subtypes with distinct cardiometabolic trait associations. The twelve genetic clusters were distinctively enriched for single-cell regulatory regions. Polygenic scores derived from the clusters differed in distribution between ancestry groups, including a significantly higher proportion of lipodystrophy-related polygenic risk in East Asian ancestry. T2D risk was equivalent at a BMI of 30 kg/m2 in the European subpopulation and 24.2 (22.9- 25.5) kg/m2 in the East Asian subpopulation; after adjusting for cluster-specific genetic risk, the equivalent BMI threshold increased to 28.5 (27.1-30.0) kg/m2 in the East Asian group, explaining about 75% of the difference in BMI thresholds. Thus, these multi-ancestry T2D genetic subtypes encompass a broader range of biological mechanisms and help explain ancestry-associated differences in T2D risk profiles.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAJD is supported by NIH/NIDDK T32 DK007028 and NIH/NIDDK F32 DK137487. KEW is supported by NIH K01DK133637. LS is supported by funds from the Ministry of Education and Science of Poland within the project Excellence Initiative-Research University, the Ministry of Health of Poland within the project Center of Artificial Intelligence in Medicine at the Medical University of Bialystok and American Diabetes Association grant 11-22-PDFPM-03. MC is supported by the Novo Nordisk Foundation (NNF21SA0072102), and NIDDK UM1 DK126185. JMM is supported by American Diabetes Association Innovative and Clinical Translational Award 1-19-ICTS-068, American Diabetes Association grant #11-22-ICTSPM-16 and by NHGRI U01HG011723. MSU is supported by NIDDK K23DK114551, NIDDK R03DK131249, and Doris Duke Foundation Award 2022063.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mass General Brigham IRB (study 2016P001018) and All of Us IRB (study 2020P002213) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll referenced GWAS summary statistics are publicly available. Eligible researchers can apply to access individual-level data in the All of Us program (researchallofus.org). Individual-level data in the Mass General Brigham biobank are only available with approval from the Mass General Brigham Institutional Review Board. Code for variant pre-processing, bNMF clustering, and basic visualizations is available on the project GitHub repository. https://github.com/gwas-partitioning/bnmf-clustering